AstraZeneca completes equity investment in Summit
5 October 2026 AstraZeneca completes equity investment in Summit Therapeutics AstraZeneca today announced the successful completion of its $2 billion equity investment in Summit Therapeutics. The equity investment will accelerate the development of ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VE…
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Inside information: Summa Defence Plc and its subsidiary Summa Holding Oy file for corporate restructuring.
- Tieto: Share repurchases on week 40
- Raute Corporation: SHARE REPURCHASE during week 40
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →